Tata Chemicals
- Market Cap
- ₹16,287 Cr
- P/E
- Not meaningful: loss-making over the last twelve months
Key Fundamentals
SmallcapChemicals & PetrochemicalsChemicalsPrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 3.42%
- Debt to Equity
- 0.35
- EPS (TTM)
- −₹92.78
- Book Value
- ₹860.55
- Market Cap
- ₹16,287 Cr
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 0.74
- ROE
- 1.27%
- Dividend Yield
- 1.69%
- EBITDA
- ₹2,121 Cr
- 52W High
- ₹854.85
- 52W Low
- ₹570.05
- Day Range
- ₹636.95 – ₹678.60
- Volume
- 39,23,477
Peer Comparison
Commodities › Chemicals & Petrochemicals › Commodity Chemicals
| 2,514.80 | 32.66 | 74,545 | 4.87 | 0.20% | 14.30% | 14.60% | 18,265 | 2,283 | |
| 1,437.20 | 15.58 | 18,143 | 2.39 | 0.68% | 11.10% | 11.40% | 12,432 | 1,164 | |
| 639.30 | — | 16,287 | 0.74 | 1.73% | 1.27% | 3.42% | 15,420 | −2,175 | |
| 3,375.55 | 100.58 | 7,303 | 9.91 | 0.13% | 20.30% | 23.90% | 784 | 70 | |
| 465.25 | 6.50 | 6,836 | 0.73 | 4.49% | 9.14% | 12.00% | 9,215 | 1,052 | |
| 593.00 | 32.85 | 4,355 | 0.82 | 3.06% | −0.05% | 1.42% | 4,772 | 133 | |
| 445.15 | 8.86 | 4,101 | 1.15 | 2.64% | 13.00% | 17.40% | 3,138 | 473 | |
| Median 7 companies | 639.30 | 24.12 | 7,303 | 1.15 | 1.73% | 11.10% | 12.00% | 9,215 | 473 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 91/100
Category scores
- Quality
- 21
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 76
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 27
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 27
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 32
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 20
- Poor
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Stock is trading at 0.74 times its book value
- Company has been maintaining a healthy dividend payout of 82.4%
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.41% over past five years.
- Company has a low return on equity of 1.59% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 4 | 7 | 8 |
| Oscillators | Bullish | 0 | 7 | 2 |
| Moving Averages | Strong Bullish | 4 | 0 | 6 |
Oscillators
Bullish
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 56.76
- Neutral
- MACD (12,26,9)
- 4.51
- Bullish
- SMA (50)
- 628.61
- Bullish
- SMA (200)
- 681.53
- Bearish
As of
Analyst Rating
1 of 7 analysts rate Buy, 2 Hold, 4 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | −0.20% |
|---|---|
| 5Y | +7.41% |
| 3Y | −4.58% |
| 1Y | −2.04% |
| TTM | +4.93% |
Net profit
| 10Y | Turned to loss |
|---|---|
| 5Y | Turned to loss |
| 3Y | Turned to loss |
| 1Y | Turned to loss |
| TTM | Turned to loss |
Operating cash flow
| 10Y | −5.90% |
|---|---|
| 5Y | −9.03% |
| 3Y | −24.69% |
| 1Y | −27.94% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −1.71 pp |
|---|---|
| 5Y | −2.38 pp |
| 3Y | −10.37 pp |
| 1Y | −0.74 pp |
| TTM | −3.28 pp |
Revenue by year
| Mar 2017 | ₹10,346 Cr |
|---|---|
| Mar 2018 | ₹10,270 Cr |
| Mar 2019 | ₹10,337 Cr |
| Mar 2020 | ₹10,357 Cr |
| Mar 2021 | ₹10,200 Cr |
| Mar 2022 | ₹12,622 Cr |
| Mar 2023 | ₹16,789 Cr |
| Mar 2024 | ₹15,421 Cr |
| Mar 2025 | ₹14,887 Cr |
| Mar 2026 | ₹14,584 Cr |
Net profit by year
| Mar 2017 | ₹1,234 Cr |
|---|---|
| Mar 2018 | ₹2,702 Cr |
| Mar 2019 | ₹1,387 Cr |
| Mar 2020 | ₹7,228 Cr |
| Mar 2021 | ₹436 Cr |
| Mar 2022 | ₹1,405 Cr |
| Mar 2023 | ₹2,434 Cr |
| Mar 2024 | ₹435 Cr |
| Mar 2025 | ₹387 Cr |
| Mar 2026 | −₹1,715 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Tata Chemicals Ltd trades at ₹649.45 as of 2026-11-17 with a market cap of ₹16,545 crore and a price-to-book ratio of 0.75, indicating a significant discount to book value. However, the company reports a negative TTM EPS of -₹92.78, a negative ROE of -7.73%, and a negative ROCE of -2.69%, reflecting deep profitability challenges. The stock sits 24% below its 52-week high of ₹854.85 while compounded profit growth over the trailing twelve months stands at -288%.
- Stock trades at a price-to-book ratio of just 0.75 as of 2026-11-17, well below book value, suggesting potential deep-value opportunity for contrarian investors
- The company has maintained a healthy dividend payout ratio of 82.4%, and the current dividend yield stands at 1.8%, providing some income cushion
- Debt-to-equity ratio is a manageable 0.36, indicating the balance sheet is not over-leveraged despite the current earnings downturn
- Compounded sales growth over 10 years is flat at 0% but the TTM revenue growth has turned positive at 5%, suggesting a possible early-stage revenue recovery
- The 5-year compounded sales growth of 7% shows the company has been able to grow its top line over medium-term cycles even if profitability lagged
- 10-year stock CAGR of 12% indicates the company has historically generated meaningful long-term shareholder returns despite recent weakness
- The stock is 24% below its 52-week high of ₹854.85 and only 14% above its 52-week low of ₹570.05, with much of the negative news potentially already priced in
- TTM EPS is deeply negative at -₹92.78, rendering the P/E ratio meaningless and signalling severe bottom-line deterioration
- ROE stands at -7.73% and ROCE at -2.69% as of the latest period, meaning the company is destroying shareholder value rather than generating returns
- Compounded profit growth over the TTM period is -288%, reflecting a dramatic swing into losses
- 3-year compounded profit growth of -51% shows the earnings decline is not a one-off event but a sustained multi-year trend
- 3-year ROE averages just 2% and last year's ROE was only 1%, indicating persistent inability to generate adequate returns on equity even before the latest deterioration
- Interest coverage ratio is low, raising concerns about the company's ability to comfortably service its debt obligations during the current earnings downturn
- 5-year compounded sales growth of roughly 7% is modest for a mid-cap company and the 3-year compounded sales growth is negative at -5%, indicating top-line contraction in the more recent period
- Stock has delivered a 1-year return of -27% and a 3-year CAGR of -14%, significantly underperforming broader market indices over these periods
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Tata Chemicals faces a mixed period dominated by the unresolved Kenya operations dispute, where its subsidiary TCML saw meaningful profit declines in FY26. A favourable court jurisdiction ruling provides some relief, but the broader regulatory and operational uncertainty in Kenya — contributing roughly 6% of consolidated EBITDA — remains an overhang. Institutional selling by a major mutual fund adds to near-term caution, and the forward outlook hinges on the resolution of the Kenya committee review and the company's ability to stabilise subsidiary earnings.
- Kenya subsidiary EBITDA decline Oct 24
TCML's EBITDA fell to ₹101 crore in FY26 from ₹142 crore in FY25, and profit after tax dropped to ₹48 crore from ₹118 crore. Revenue also declined to ₹586 crore from ₹612 crore.
- Kenya operations dispute ongoing Oct 24
An ongoing dispute between TCML and Kenya's Ministry of Mining led to a reported directive to cease operations. A high-level committee formed after a Sep 8 meeting is conducting a technical review, with outcomes still pending.
- Major MF cuts stake sharply Nov 6
ICICI Prudential Mutual Fund sold 52.55 lakh shares via open market, reducing its holding to 2.94% from 5.01% — a significant institutional reduction.
- Kenya court ruling favours Tata Oct 24
Kenya's High Court ruled on Oct 23 that it lacks jurisdiction over the TCML dispute and cannot take further steps, removing one legal overhang for the subsidiary.
- Company denies IPO reports Nov 17
Tata Chemicals responded to a BSE inquiry about IPO-related news, denying knowledge of any negotiations or undisclosed details.
- Analyst meet on Nov 16 Nov 11
Tata Chemicals confirmed participation in the JM Financial Annual India Conference on Nov 16 in Mumbai, with no unpublished price sensitive information to be shared.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,998 | 3,730 | 3,475 | 3,789 | 3,999 | 3,590 | 3,509 | 3,719 | 3,877 | 3,550 | 3,438 | 4,255 | 4,177 |
| Expenses | 3,191 | 3,188 | 3,032 | 3,215 | 3,381 | 3,156 | 3,182 | 3,070 | 3,340 | 3,205 | 3,164 | 3,717 | 3,796 |
| Operating Profit | 807 | 542 | 443 | 574 | 618 | 434 | 327 | 649 | 537 | 345 | 274 | 538 | 381 |
| OPM % | 20% | 15% | 13% | 15% | 15% | 12% | 9% | 17% | 14% | 10% | 8% | 13% | 9% |
| Other Income | 85 | 98 | −861 | 116 | 152 | −10 | 29 | 138 | 128 | 21 | −1,760 | 56 | 115 |
| Interest | 145 | 132 | 130 | 133 | 145 | 148 | 137 | 147 | 144 | 146 | 153 | 148 | 151 |
| Depreciation | 234 | 246 | 271 | 273 | 277 | 280 | 293 | 280 | 285 | 293 | 343 | 336 | 351 |
| Exceptional Items | 102 | — | — | — | — | — | — | — | — | — | — | — | — |
| PBT | 615 | 262 | −819 | 284 | 348 | −4 | −74 | 360 | 236 | −73 | −1,982 | 110 | −6 |
| Tax % | 20% | 26% | 3% | 33% | 23% | 425% | −34% | 12% | 35% | −5% | 7% | 45% | 733% |
| Net Profit | 495 | 194 | −841 | 190 | 267 | −21 | −49 | 316 | 154 | −69 | −2,116 | 60 | −50 |
| EPS (₹) | 16.80 | 6.20 | −33.36 | 5.89 | 7.61 | −2.08 | −2.20 | 9.89 | 3.02 | −3.65 | −83.67 | −0.67 | −4.79 |
| YoY Sales growth | −6 | −10 | −21 | −10 | 0 | −4 | 1 | −2 | −3 | −1 | −2 | 14 | 8 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17,204 | 14,873 | 10,346 | 10,270 | 10,337 | 10,357 | 10,200 | 12,622 | 16,789 | 15,421 | 14,887 | 14,584 | 15,420 |
| Expenses | 15,305 | 12,777 | 8,249 | 6,926 | 8,538 | 8,411 | 8,693 | 10,303 | 12,969 | 12,574 | 12,934 | 12,779 | 13,882 |
| Operating Profit | 1,900 | 2,096 | 2,097 | 3,344 | 1,799 | 1,945 | 1,506 | 2,319 | 3,820 | 2,847 | 1,953 | 1,805 | 1,538 |
| OPM % | 11% | 14% | 20% | 33% | 17% | 19% | 15% | 18% | 23% | 18% | 13% | 12% | 10% |
| Other Income | 183 | 210 | 293 | 262 | 785 | 6,480 | 254 | 472 | 218 | −507 | 287 | −1,473 | −1,568 |
| Interest | 461 | 525 | 297 | 326 | 354 | 342 | 367 | 303 | 406 | 530 | 563 | 590 | 598 |
| Depreciation | 463 | 526 | 512 | 518 | 568 | 666 | 759 | 806 | 892 | 980 | 1,123 | 1,201 | 1,323 |
| PBT | 1,159 | 1,255 | 1,580 | 2,763 | 1,661 | 7,416 | 634 | 1,682 | 2,742 | 830 | 554 | −1,459 | −1,951 |
| Tax % | 30% | 20% | 22% | 2% | 17% | 3% | 31% | 16% | 11% | 46% | 30% | 18% | — |
| Net Profit | 802 | 1,006 | 1,234 | 2,702 | 1,387 | 7,228 | 436 | 1,405 | 2,434 | 435 | 387 | −1,715 | −2,175 |
| EPS (₹) | 23.41 | 30.24 | 38.98 | 95.49 | 45.37 | 274.97 | 10.06 | 49.36 | 90.93 | 10.52 | 9.22 | −74.41 | −92.78 |
| Div. Payout % | 53% | 33% | 28% | 23% | 28% | 4% | 99% | 25% | 19% | 143% | 119% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | — |
| Sales growth | 8 | −14 | −30 | −1 | 1 | 0 | −2 | 24 | 33 | −8 | −3 | −2 | 5 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 |
| Reserves | 5,297 | 6,600 | 7,653 | 10,847 | 12,086 | 12,643 | 14,035 | 17,998 | 19,466 | 21,986 | 21,339 | 20,951 | 21,668 |
| Borrowings | 8,379 | 9,090 | 7,072 | 6,108 | 6,130 | 7,702 | 6,933 | 7,025 | 6,296 | 5,563 | 7,072 | 8,001 | 7,762 |
| Other Liabilities | 6,872 | 8,402 | 8,607 | 8,648 | 8,398 | 7,073 | 7,115 | 8,566 | 8,923 | 8,907 | 9,084 | 9,791 | 9,640 |
| Total Liabilities | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 | 38,998 | 39,325 |
| Fixed Assets | 11,359 | 13,431 | 12,644 | 12,787 | 13,551 | 15,356 | 15,261 | 16,044 | 17,092 | 17,861 | 19,600 | 20,602 | 20,798 |
| CWIP | 189 | 350 | 333 | 409 | 774 | 835 | 1,094 | 1,667 | 2,410 | 2,217 | 1,913 | 1,038 | 908 |
| Investments | 443 | 2,188 | 2,787 | 2,840 | 5,615 | 4,285 | 5,816 | 7,683 | 7,448 | 9,739 | 9,144 | 9,886 | 9,482 |
| Other Assets | 8,811 | 8,377 | 7,822 | 9,822 | 6,929 | 7,198 | 6,167 | 8,449 | 7,990 | 6,894 | 7,093 | 7,472 | 8,137 |
| Total Assets | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 | 38,998 | 39,325 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1,274 | 2,332 | 3,531 | 1,870 | 1,581 | 1,780 | 2,037 | 1,644 | 2,971 | 3,016 | 1,761 | 1,269 |
| Investing | −663 | −463 | −985 | 2,714 | −1,927 | −2,285 | −1,147 | −817 | −1,149 | −605 | −1,667 | −766 |
| Financing | −1,087 | −1,802 | −2,341 | −2,089 | −1,712 | −129 | −1,456 | −755 | −2,076 | −2,494 | 29 | −670 |
| Net Cash Flow | −477 | 68 | 205 | 2,494 | −2,058 | −634 | −565 | 72 | −254 | −83 | 123 | −167 |
| Free Cash Flow | 709 | 1,645 | 2,888 | 1,140 | 502 | 611 | 804 | 379 | 1,427 | 1,193 | −191 | 129 |
| CFO/EBITDA | 86 | 129 | 190 | 71 | 115 | 99 | 142 | 82 | 88 | 120 | 102 | 67 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 88 | 74 | 46 | 51 | 56 | 50 | 56 | 57 | 45 | 47 | 52 |
| Inventory Days | 137 | 119 | 244 | 304 | 315 | 347 | 257 | 317 | 282 | 341 | 324 | 353 |
| Days Payable | 138 | 99 | 232 | 307 | 269 | 302 | 256 | 338 | 289 | 320 | 318 | 293 |
| Cash Conversion Cycle | 72 | 107 | 86 | 43 | 97 | 100 | 51 | 35 | 50 | 66 | 53 | 113 |
| Working Capital Days | −4 | 31 | −4 | 27 | −2 | −102 | −28 | −29 | 29 | −22 | −21 | −17 |
| ROCE % | 11% | 11% | 10% | 16% | 9% | 36% | 4% | 8% | 12% | 8% | 4% | 3% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Tata Chemicals insights
69 extracted metrics across FY11–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- 5 Dec 2025
- 1 Dec 2025
- 6 Oct 2025
- 6 May 2025
- 7 Oct 2024
- General announcements 11 Nov 2026
Frequently Asked Questions about Tata Chemicals
What does Tata Chemicals Ltd do?
Where is Tata Chemicals Ltd (TATACHEM) listed?
Which sector does Tata Chemicals Ltd belong to?
What is the market capitalisation of Tata Chemicals Ltd?
What is the 52-week high and low of Tata Chemicals Ltd?
Does Tata Chemicals Ltd pay dividends?
What is the Return on Equity (ROE) of Tata Chemicals Ltd?
Company Information
Incorporated in 1939, Tata Chemicals Ltd manufactures and exports basic chemistry and specialty products
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TATACHEM.md for Tata Chemicals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.